Breast Cancer Awareness Month brings attention to important advancements in cancer care, and today, we're partnering with ...
Astrazeneca is set to report earnings next week after a turbulant few months for the FTSE 100 firm and its China arm.
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Shareholders in Disney will see if CEO Bob Iger still has a midas touch and in Asia, Alibaba is expected to deliver yet ...
AstraZeneca CEO Pascal Soriot acknowledged when the company announced the Eccogene deal in November 2023 that his company was "a few years behind" the roaring success of Novo Nordisk and Eli Lilly ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...
Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback